The pipeline products include E2HSA and other approved type 2 diabetes treatment combination drugs, weight management drugs, interleukin-2 fusion protein tumor treatment adjuvant drugs.

Product	Use	Preclinical research, clinical phase I, clinical phase II, clinical phase III	Estimated completion date for the current phase
E2HSA	Type 2 diabetes injection, GLP-1 weekly preparation, minimal hypoglycemia		December 2021
E2HSA+Metformin	To treat type 2 diabetes, in combination with metformin		December 2024
Interleukin-2 fusion protein	Adjuvant drugs for cancer treatment		Second half of 2022